IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

Patients Registration

•It is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms.

Procedure

•six months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Inclusion Criteria:

• The patient from over 16 years to under 75 years

• Patients diagnosed with asthma over six months ago

• immunoglobulin G subtypes who were diagnosed with immune deficiency

• more than 2 years Upper and lower respiratory tract infections

  , and asthma exacerbations in this regard.

• ① calculated creatinine clearance ≧ 50ml/min

  • ALT and AST <x 3 times the upper limit of normal

    • ALP <x 3 times the upper limit of normal

      • total bilirubin <x 1.5 times the upper limit of normal

Exclusion Criteria:

• within six months of the onset of the experiment who received immunoglobulin therapy
• immune globulin for those with a history of hypersensitivity reactions
• six months ago, another clinical trial participants.
• Systemic steroids and immunomodulators, such as asthma control that may affect the resources required drug administration.
• pregnant or lactating women.